Idecabtagene vicleucel is in clinical development for the treatment of adult patients with relapsed
or refractory multiple myeloma (MM) who have received at least 2 but no greater than 4 prior
MM regimens. MM is a rare, incurable blood cancer that forms in the plasma calls in the bone
marrow, inside some of the large bones of the body. The cancerous cells build up and interfere
with production of red and white blood cells, and platelets
Idecabtagene vicleucel for treating relapsed or
refractory multiple myeloma after 2 therapies
Idecabtagene vicleucel is in clinical development for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least 2 but no greater than 4 prior MM regimens.
Interventions:
Idecabtagene vicleucel (Ide-cel; bb2121)
Indications:
Multiple myeloma (MM)
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2022